Strategic Integration DORC’s integration with ZEISS Group as of April 2025 positions their EVA NEXUS platform within a larger, established ophthalmic technology ecosystem, creating cross-selling opportunities for ZEISS customers and expanding access to integrated retina, cataract, and surgical workflow solutions.

Product Adoption TissueBlue FDA-approved staining solution has broad user adoption in the US (over 100,000 surgeries and preference by more than 40% of US retina surgeons), indicating high product credibility and opportunities to upsell complementary instruments, disposables, or enhanced imaging capabilities.

Global Reach With international reach including Health Canada approvals and new European distributor partnerships, there are openings to expand sales through additional geographic channels and to tailor regulatory-compliant bundles for regional markets.

Technology Stack Utilize current tech stack signals—cloud, collaboration, and web-enabled platforms—to offer modernized sales demos, remote training, and scalable support for EVA NEXUS, TissueBlue, and other ophthalmic solutions to streamline procurement for mid-market clinics.

Growth Potential Relatively small company size and revenue in the low-to-mid multi-million range suggest high scalability potential through channel partnerships, distributor expansion, and targeted outreach to mid-sized ophthalmic practices seeking integrated surgical solutions.